Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 2/20 | 0.60 |
| ▸ | KLK1 | P06870 | 2/20 | 0.58 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA4 | P22748 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3472698 | 0.84 | PDE4B (0.85) | PDE4BKLK1KLK5CA1CA2 | |
| SCHEMBL13637188 | 0.83 | CA12 (0.57) | PDE4BKLK1KLK5CA12CA1 | |
| SCHEMBL13111041 | 0.81 | PDE4B (0.57) | PDE4BKLK1KLK5 | |
| SCHEMBL2530691 | 0.81 | PDE4B (0.74) | PDE4B | |
| SCHEMBL3473905 | 0.78 | CA12 (0.53) | PDE4BKLK1KLK5CA12CA1 | |
| SCHEMBL3472754 | 0.78 | PDE4B (0.83) | PDE4BKLK1KLK5 | |
| SCHEMBL2530683 | 0.78 | PDE4B (0.79) | PDE4B | |
| SCHEMBL3475972 | 0.78 | CA12 (0.59) | PDE4BKLK1KLK5CA12CA1 | |
| SCHEMBL13111069 | 0.77 | PDE4B (0.52) | PDE4BKLK1KLK5 | |
| SCHEMBL22939827 | 0.77 | CA1 (0.73) | KLK1KLK5CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256092-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-20100256092-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-20100256092-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2010-10-07 | — | — | US | disclosed |
| WO-2009140309-A2 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2009-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256092-A1 | BORON-CONTAINING SMALL MOLECULES | BCL6B, BCL6, BTD | PDE4B 1890/4885KLK1 1578/4885KLK5 1864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.